Mortensen, Anja C. L.
Morin, Eric
Brown, Christopher J.
Lane, David P.
Nestor, Marika
Funding for this research was provided by:
VetenskapsrÄdet (2013-30876-104113-30)
Cancerfonden (CAN 2015/, CAN 2015/385)
Article History
Received: 21 June 2019
Accepted: 16 October 2019
First Online: 16 April 2020
Ethics approval and consent to participate
: Not applicable.
: All authors agree with the submission and have approved the submitted manuscript.
: The authors declare that they have no competing interests for the submitted work. Sir David Lane is an employee of Chugai and receives support from Merck, Ipsen and Asian. Sir Lane and Dr Brown are involved in a collaborative project with Merck on macrocyclic peptides and have a patent issued (WO2014055039A1) on Peptides and Methods for Treating Cancer.